Filtered By:
Drug: Metformin

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 9821 results found since Jan 2013.

Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On!
Abstract Since their introduction to clinical practice in the 1950s, sulfonylureas have been widely prescribed for use in patients with type 2 diabetes. Of all the other medications currently available for clinical use, only metformin has been used more frequently. However, several new drug classes have emerged that are reported to have equal glucose-lowering efficacy and greater safety when added to treatment of patients in whom metformin monotherapy is no longer sufficient. Moreover, current arguments also suggest that the alternative drugs may be superior to sulfonylureas with regard to the risk of cardiovascul...
Source: Diabetes Care - January 1, 2015 Category: Endocrinology Authors: Genuth S Tags: Diabetes Care Source Type: research

Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!
Abstract Since their introduction to clinical practice in the 1950s, sulfonylureas have been widely prescribed for use in patients with type 2 diabetes. Of all the other medications currently available for clinical use, only metformin has been used more frequently. However, several new drug classes have emerged that are reported to have equal glucose-lowering efficacy and greater safety when added to treatment of patients in whom metformin monotherapy is no longer sufficient. Moreover, current arguments also suggest that the alternative drugs may be superior to sulfonylureas with regard to the risk of cardiovascul...
Source: Diabetes Care - January 1, 2015 Category: Endocrinology Authors: Abrahamson MJ Tags: Diabetes Care Source Type: research

Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin.
CONCLUSIONS: Combinations of empagliflozin/linagliptin as second-line therapy for 52 weeks significantly reduced HbA1c compared with the individual components and were well tolerated. PMID: 25583754 [PubMed - as supplied by publisher]
Source: Diabetes Care - January 12, 2015 Category: Endocrinology Authors: DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC Tags: Diabetes Care Source Type: research

Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial.
CONCLUSIONS: Dapagliflozin was well tolerated and effective over 24 weeks as add-on to metformin plus sulfonylurea. Adverse effects included hypoglycemia and genital infections. PMID: 25592197 [PubMed - as supplied by publisher]
Source: Diabetes Care - January 15, 2015 Category: Endocrinology Authors: Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S, for the Study 05 Group Tags: Diabetes Care Source Type: research

Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010.
CONCLUSIONS: There was a significant increase in diabetes treatment intensification between 2002 and 2010. Choice of secondline agents changed as well, with decreasing prevalence of thiazolidinedione and sulfonylurea use and rising prevalence of incretin use. PMID: 26167776 [PubMed - in process]
Source: The American Journal of Managed Care - July 17, 2015 Category: Health Management Authors: McCoy RG, Zhang Y, Herrin J, Denton BT, Mason JE, Montori VM, Smith SA, Shah ND Tags: Am J Manag Care Source Type: research

Infertility in a young woman with Type 2 diabetes.
This article outlines the pathophysiology of PCOS and its diagnostic pathways and also summarises the safety of medical management for the metabolic complications in pregnant women. It is important for healthcare professionals to be aware of the latest guidance for treatment of PCOS in order to provide high-standard evidencebased care. PMID: 26217407 [PubMed]
Source: Primary Care - August 1, 2015 Category: Primary Care Authors: Szaboova R, Devendra S Tags: London J Prim Care (Abingdon) Source Type: research

Screening for Insulin Resistance in Polycystic Ovary Syndrome: Views of Physician Members of the American Society for Reproductive Medicine.
CONCLUSION: Two-thirds of ASRM physician members surveyed screen women with PCOS for IR in spite of the lack of general consensus on the need for such screening from endocrine societies. PMID: 26592060 [PubMed - in process]
Source: Journal of Reproductive Medicine - November 27, 2015 Category: Reproduction Medicine Tags: J Reprod Med Source Type: research

Personalized medicine in diabetes: the role of ‘omics’ and biomarkers
This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - January 23, 2016 Category: Endocrinology Authors: E. Pearson Tags: Review Source Type: research

Cost-effectiveness of diabetes treatment sequences to inform step therapy policies.
CONCLUSIONS: Assuming a $50,000 willingness-to-pay threshold, adding an SGLT2 inhibitor was cost-effective compared with switching from a DPP-4 inhibitor to a GLP-1 RA from a private payer perspective but not from a public payer perspective. This study highlights how differences in payer reimbursement rates for medications can lead to contrasting results. PMID: 32181619 [PubMed - as supplied by publisher]
Source: The American Journal of Managed Care - February 29, 2020 Category: Health Management Authors: Hung A, Jois B, Lugo A, Slejko JF Tags: Am J Manag Care Source Type: research

Screening for Diabetes and Prediabetes Should be Cost-Saving in Patients at High Risk.
CONCLUSIONSFrom a health economics perspective, screening for diabetes and high-risk prediabetes should target patients at higher risk, particularly those with BMI >35 kg/m(2), systolic blood pressure ≥130 mmHg, or age older than 55 years, for whom screening can be most cost-saving. GCTpl is generally the least expensive test in high-risk groups and should be considered for routine use as an opportunistic screen in these groups. PMID: 23393215 [PubMed - as supplied by publisher]
Source: Diabetes Care - February 7, 2013 Category: Endocrinology Authors: Chatterjee R, Narayan KM, Lipscomb J, Jackson SL, Long Q, Zhu M, Phillips LS Tags: Diabetes Care Source Type: research

Determinants of Maternal Triglycerides in Women With Gestational Diabetes Mellitus in the Metformin in Gestational Diabetes (MiG) Study.
CONCLUSIONSAt 36 weeks, maternal triglycerides were related to glucose control in women treated with insulin and ethnicity in women treated with metformin. Whether there are ethnicity-related dietary changes or differences in metformin response that alter the relationship between glucose control and triglycerides requires further study. PMID: 23393209 [PubMed - as supplied by publisher]
Source: Diabetes Care - February 7, 2013 Category: Endocrinology Authors: Barrett HL, Nitert MD, Jones L, O'Rourke P, Lust K, Gatford KL, De Blasio MJ, Coat S, Owens JA, Hague WM, McIntyre HD, Callaway L, Rowan J Tags: Diabetes Care Source Type: research

Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.
CONCLUSIONS: Over 10 years, lifestyle intervention and metformin were cost-effective or cost saving compared with placebo. These analyses confirm that lifestyle and metformin represent a good value for money. PMID: 23544761 [PubMed - in process]
Source: The American Journal of Managed Care - March 1, 2013 Category: Health Management Authors: Herman WH, Edelstein SL, Ratner RE, Montez MG, Ackermann RT, Orchard TJ, Foulkes MA, Zhang P, Saudek CD, Brown MB, Diabetes Prevention Program Research Group Tags: Am J Manag Care Source Type: research

Empagliflozin As Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial.
CONCLUSIONSEmpagliflozin 10 and 25 mg for 24 weeks as add-on to metformin plus sulfonylurea improved glycemic control, weight, and systolic blood pressure and were well tolerated. PMID: 23963895 [PubMed - as supplied by publisher]
Source: Diabetes Care - August 20, 2013 Category: Endocrinology Authors: Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC, on behalf of the EMPA-REG METSU™ Trial Investigators Tags: Diabetes Care Source Type: research

Quality measure attainment in patients with type 2 diabetes mellitus.
Conclusion: This study highlights the high incidence of comorbidities and potential financial implications of attaining T2DM quality outcomes. PMID: 24512194 [PubMed - in process]
Source: The American Journal of Managed Care - January 1, 2014 Category: Health Management Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P Tags: Am J Manag Care Source Type: research

Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Conclusion: In this study involving patients with T2DM on metformin plus sulfonylurea, after 52 weeks, patients treated with canagliflozin 300 mg demonstrated better attainment of individual and composite diabetes-related quality measures compared with patients treated with sitagliptin 100 mg. PMID: 24512193 [PubMed - in process]
Source: The American Journal of Managed Care - January 1, 2014 Category: Health Management Authors: Bailey RA, Damaraju CV, Martin SC, Meininger GE, Rupnow MF, Blonde L Tags: Am J Manag Care Source Type: research